Simple T cell activation in 2 weeks with ImmPACT

- T cell from patients blood are activated by cancer-antigen presentation and stimulatory molecules to mediate tumor killing
- ImmPACT creates a strong multitargeted and polyclonal T cell product with an advantageous phenotype and high cytotoxic profile
- All T cell clones are endogenous to patients, ensuring “pre-validation” of off-tumor safety
- ImmPACT’s cell product is blood-based with a simple ex-vivo manufacturing process delivering treatments only 2 weeks from blood draw
Multitargeted cell products – Neoantigens selected with AIM
- Optimal immunogenic neoantigens are identified with PokeAcell’s proprietary AIM predictor
- AIM build on the largest known datasets on T cell recognition of neoantigens in cancer patients
- Multiple antigen peptides can be pursued in the same cell product and each cancer antigen creates a range of polyclonal T cells

Publications
Ulla Kring Hansen, Rikke Lyngaa, Dafina Ibrani, Candice Church, Monique Verhaegen, Andrzej Antoni Dlugosz, Jürgen Christian Becker, Per Thor Straten, Paul Nghiem and Sine Reker Hadrup
Kevin Litchfield, James L. Reading, Clare Puttick, Krupa Thakkar, Chris Abbosh, Robert Bentham, Thomas B.K. Watkins, Rachel Rosenthal, Dhruva Biswas, Andrew Rowan, Emilia Lim, Maise Al Bakir, Virginia Turati,4 Jose´ Afonso Guerra-Assunc¸ Lucia Conde, Andrew J.S. Furness, Sunil Kumar Saini, Sine R. Hadrup, Javier Herrero, Se-Hoon Lee, Peter Van Loo, Tariq Enver, James Larkin, Matthew D. Hellmann, Samra Turajlic, Sergio A. Quezada*, Nicholas McGranahan, and Charles Swanton
Sunil Kumar Saini, Tripti Tamhane, Raghavendra Anjanappa, Ankur Saikia, Sofie Ramskov, Marco Donia, Inge Marie Svane, Søren Nyboe Jakobsen, Maria Garcia-Alai, Martin Zacharias, Rob Meijers, Sebastian Springer, Sine Reker Hadrup
Nadia Viborg, Sofie Ramskov, Rikke Sick Andersen, Theo Sturmc, Tim Fugmann, Amalie Kai Bentzen, Vibeke Mindahl Rafaa, Per thor Straten, Inge Marie Svane, Özcan Met, and Sine Reker Hadrup
An analysis of natural T cell responses to Predicted Tumor neoepitopes, Frontiers in Immunology 2017
Anne-Mette Bjerregaard, Morten Nielsen, Vanessa Jurtz, Carolina M. Barra, Sine Reker Hadrup, Zoltan Szallasi and Aron Charles Eklund
MuPeXI: prediction of neo‑epitopes from tumor sequencing data, Cancer Immunol Immunother 2017
Anne‑Mette Bjerregaard, Morten Nielsen, Sine Reker Hadrup, Zoltan Szallasi, Aron Charles Eklund
Amalie Kai Bentzen, Andrea Marion Marquard, Rikke Lyngaa, Sunil Kumar Saini, Sofie Ramskov, Marco Donia, Lina Such, Andrew J S Furness, Nicholas McGranahan, Rachel Rosenthal, Per thor Straten, Zoltan Szallasi, Inge Marie Svane, Charles Swanton, Sergio A Quezada, Søren Nyboe Jakobsen, Aron Charles Eklund and Sine Reker Hadrup
Nicholas McGranahan, Andrew J. S. Furness, Rachel Rosenthal, Sofie Ramskov, Rikke Lyngaa, Sunil Kumar Saini, Mariam Jamal-Hanjani, Gareth A. Wilson, Nicolai J. Birkbak, Crispin T. Hiley, Thomas B. K. Watkins, Seema Shafi, Nirupa Murugaesu, Richard Mitter, Ayse U. Akarca, Joseph Linares, Teresa Marafioti, Jake Y. Henry, Eliezer M. Van Allen, Diana Miao, Bastian Schilling, Dirk Schadendorf, Levi A. Garraway, Vladimir Makarov, Naiyer A. Rizvi, Alexandra Snyder, Matthew D. Hellmann, Taha Merghoub, Jedd D. Wolchok, Sachet A. Shukla, Catherine J. Wu, Karl S. Peggs, Timothy A. Chan, Sine R. Hadrup, Sergio A. Quezada, and Charles Swanton
Rikke Lyngaa, Natasja Wulff Pedersen, David Schrama, Charlotte Albæk Thrue, Dafina Ibrani, Ozcan Met, Per thor Straten, Paul Nghiem, Jürgen C. Becker, and Sine Reker Hadrup
Rikke Sick Andersen, Pia Kvistborg, Thomas Mørch Frøsig, Natasja W Pedersen, Rikke Lyngaa1, Arnold H Bakker, Chengyi Jenny Shu, Per thor Straten, Ton N Schumacher & Sine Reker Hadrup